• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Poland Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Poland Pharmaceuticals and Healthcare Report Q1 2013

  • Published: January 2013
  • Region: Poland
  • 102 pages
  • Business Monitor International

FEATURED COMPANIES

  • Bioton
  • Company Profiles
  • Eli Lilly
  • Gedeon Richter
  • GlaxoSmithKline
  • Krka
  • MORE

BMI View:

The Polish pharmaceutical market contracted severely in 2012, owing to harsh pricing measures and strict margins imposed on wholesalers, pharmaceutical makers and retailers. Moreover,
over the course of the year, the burden of pharmaceutical spending has shifted towards the Polish consumer, as the harsher reimbursement regime has caused private contributions to prescription payments rise. We forecast a return to growth in 2013, driven by private consumption as the Polish government entrenches cuts to drug expenditure. We expect strong growth in the medium to long term as Poland's economy diversifies and aligns with developed countries. The growth of private medical companies is a positive development in the Polish healthcare market, and the possible introduction of voluntary health insurance could lead to a greater role for the private sector in healthcare provision.

Headline Expenditure Projections

- Pharmaceuticals: PLN33.37bn (US$11.26bn) in 2011 to PLN31.38bn (US$9.62bn) in 2012;
-5.98% in local currency terms and -14.5 % in US dollar terms.

- Healthcare: PLN112.18bn (US$37.85bn) in 2011 to PLN118.57bn (US$36.37bn) in 2012;
+5.2% in READ MORE >

Executive Summary 6

SWOT Analysis 8

Poland Pharmaceuticals Industry SWOT 8

Poland Political SWOT 9

Poland Economic SWOT 9

Poland Business Environment SWOT 10

Pharmaceutical Risk/Reward Ratings 11
Table: Central And Eastern Europe Pharmaceuticals Risk/Reward Ratings, Q113 11

Rewards 12

Risks 13

Poland - Market Summary 15

Regulatory Regime 16

Advertising Regulations 17

Other Regulatory Developments 18

Intellectual Property Regime 18

Intellectual Property Shortcomings 19

Pricing And Reimbursement Regime 20

Pricing Policies 21

Drug Price Inflation 22

Reimbursement Policies 23

Reimbursement Regime Changes 24

Industry Trends And Developments 27

Epidemiology 27

Healthcare System 28

Hospital Infrastructure 29

Ambulatory Infrastructure 29
Table: Civilian Outpatient Facilities, 2002-2009 30

Hospital Privatisation 30

Health Insurance 31

Distribution Channels 33

EU Directive 33

Drug Wholesaling 33

Leading Wholesalers 33

ACP Pharma 33

Cefarm 34
Table: Cefarm's Financial Indicators, 2007-2010 (Million Zlotys) 34

Phoenix Pharma Polska 34

Pelion Healthcare Group 35

Research & Development 36

Clinical Trials 36

Developments In The Clinical Trials Sector 37

Medical Devices 38

Industry Forecast Scenario 40

Overall Market Forecast 40
Table: Pharmaceutical Sales, Historical Data and Forecasts 42

Key Growth Factors - Healthcare 43
Table: Healthcare Expenditure Trends, Historical Data and Forecasts 46
Table: Government Healthcare Expenditure Trends, Historical Data and Forecasts 47
Table: Private Healthcare Expenditure Trends, Historical Data and Forecasts 47

Key Growth Factors - Macroeconomic 48
Table: Long-Term Macroeconomic Forecasts 51

Prescription Drug Market Forecast 52
Table: Prescription Drug Market Indicators, Historical Data and Forecasts 52

Patented Drug Market Forecast 54
Table: Patented Drug Market Indicators, Historical Data and Forecasts 55

Generic Drug Market Forecast 56
Table: Poland Generics Drug Market Indicators, Historical Data and Forecasts 57

OTC Medicine Market Forecast 58
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts 59

Pharmaceutical Trade Forecast 60
Table: Pharmaceutical Trade Data And Forecasts (US$mn) 63
Table: Pharmaceutical Trade Data And Forecasts (PLNmn) 63

Medical Device Market Forecast 64
Table: Medical Device Market Indicators, Historical Data and Forecasts 64

Competitive Landscape 66

Pharmaceutical Industry 66

Domestic Industry 66

Domestic Company Developments 67

Foreign Industry 70

Foreign Company Developments 71

Pharmaceutical Wholesale Sector 72

Pharmaceutical Retail Sector 75
Table: Number Of Pharmacies In Poland, 2004-2009 75

Company Profiles 76

Local Companies 76

Polpharma 76

Bioton 78

Multinational Companies 81

GlaxoSmithKline 81

Eli Lilly 84

Gedeon Richter 86

Krka 88

Lek (Sandoz/Novartis) 90

Demographic Outlook 92
Table: Population By Age Group, 1990-2020 ('000) 93
Table: Population By Age Group, 1990-2020 (% of total) 94
Table: Key Population Ratios, 1990-2020 95
Table: Rural And Urban Population, 1990-2020 95

Glossary 96

BMI Methodology 98

How We Generate Our Pharmaceutical Industry Forecasts 98

Pharmaceutical Risk/Reward Ratings Methodology 99

Ratings Overview 99
Table: Pharmaceutical Risk/Reward Indicators 00

Weighting 01
Table: Weighting Of Components 01

Sources 01

Company Profiles
Local Companies
Polpharma
Bioton
Multinational Companies
GlaxoSmithKline
Eli Lilly
Gedeon Richter
Krka
Lek (Sandoz/Novartis)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos